RiboLife’s RBD1016 Earns EMA Orphan Designation with RiboGalSTAR Platform
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that...
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced today that...
China-based Suzhou Ribo Life Science Co., Ltd announced the completion of subject enrollment for the...
China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received...
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that...
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...
China-based Suzhou Ribo Life Science Co., Ltd reportedly raised USD 40 million in a Series...